Will the expiration of bedaquiline's patent increase its availability worldwide?

Short answer: mostly yes, but not automatically or everywhere.

How it would help
- Patent expiry typically allows generic manufacturers to enter the market, which usually lowers prices and increases supply.
- For bedaquiline, there is already a framework (voluntary licenses with Medicines Patent Pool) that has allowed generic production in many low- and middle-income countries. Expiry of core bedaquiline patents would likely expand generic availability to additional markets and potentially reduce prices further.

Caveats and things that could blunt the effect
- Not automatic: even after patent expiry, a country still needs regulatory approval, quality testing, and a procurement mechanism to actually get generics into clinics.
- Other barriers: some countries may have data exclusivity, additional patents (second-use or formulation patents), or regulatory data protection that can delay entry of generics.
- Supply and demand: manufacturers need the capability and incentives to produce at scale; funding and supply chain logistics must be in place, especially for MDR-TB programs.
- Voluntary licensing landscape: the existing licenses (e.g., with MPP) help expand access in many places, and the terms of those licenses can influence how quickly supply grows even as patents expire in other markets.
- High-income markets: some wealthier countries may keep price and access constraints higher due to confidential pricing, or may have patent protection that isn’t directly tied to bedaquiline’s core patent.

Bottom line
- In general, patent expiry should increase global availability of bedaquiline over time, primarily through cheaper generics and broader market entry. But the degree and speed of that increase depend on regulatory approvals, national procurement, funding, and any other patent or regulatory barriers in specific countries.

If you’d like, I can check the current patent status and licensing landscape by region to give a more region-specific outlook.